News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Price Tag May Be The Challenge For Novartis AG (NVS) And Juno Therapeutics' Magical Cancer Drugs



10/8/2014 6:25:40 AM

Cutting-edge cancer treatments from Switzerland's Novartis AG and Seattle's own Juno Therapeutics show great promise in clinical trials, but might face roadblocks when it comes to the costs of getting those drugs to patients, the Wall Street Journal recently reported.

Both of the companies sponsored clinical trials in which experimental chimeric antigen receptor (CAR) T-cell therapies were used on patients, 90 percent of whom saw their leukemia disappear, according to the Journal.

CAR T-cell therapies are a type of immunotherapy that engineers patients' immune cells to battle their own cancer and is used as an alternative to chemotherapy and radiation therapy.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES